{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:48:08Z","timestamp":1784126888083,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T00:00:00Z","timestamp":1414540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T00:00:00Z","timestamp":1414540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40265-014-0300-y","type":"journal-article","created":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T16:26:46Z","timestamp":1414513606000},"page":"2153-2160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Rifaximin: A Review of Its Use in Reducing Recurrence of Overt Hepatic Encephalopathy Episodes"],"prefix":"10.1007","volume":"74","author":[{"given":"Lesley J.","family":"Scott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,29]]},"reference":[{"key":"300_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/HMER.S11988","volume":"3","author":"MD Iadevaia","year":"2011","unstructured":"Iadevaia MD, Prete AD, Cesaro C, et al. Rifaximin in the treatment of hepatic encephalopathy. Hepat Med Evid Res. 2011;3:109\u201317.","journal-title":"Hepat Med Evid Res."},{"key":"300_CR2","doi-asserted-by":"publisher","unstructured":"Poh Z, Chang PEJ. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol. 2012. doi:10.1155\/2012\/480309.","DOI":"10.1155\/2012\/480309"},{"issue":"5 Pt 2","key":"300_CR3","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1592\/phco.30.pt2.10S","volume":"30","author":"TD Schiano","year":"2010","unstructured":"Schiano TD. Clinical management of hepatic encephalopathy. Pharmacotherapy. 2010;30(5 Pt 2):10S\u20135S.","journal-title":"Pharmacotherapy."},{"issue":"Supp","key":"300_CR4","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.1016\/S0168-8278(14)60640-1","volume":"60","author":"JG Orr","year":"2014","unstructured":"Orr JG, et al. Resource use associated with hepatic encephalopathy in patients with liver disease [abstract no. P478]. J Hepatol. 2014;60(Supp):S228\u20139.","journal-title":"J Hepatol"},{"key":"300_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrgastro.2010.116","volume":"7","author":"R Prakash","year":"2010","unstructured":"Prakash R, Mullen K. Mechanisms, diagnosis and mangement of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010;7:515\u201325.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"2","key":"300_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/hep.27210","volume":"60","author":"H Vilstrup","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715\u201335.","journal-title":"Hepatology."},{"issue":"4","key":"300_CR7","doi-asserted-by":"publisher","first-page":"e60042","DOI":"10.1371\/journal.pone.0060042","volume":"8","author":"JS Bajaj","year":"2013","unstructured":"Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8(4):e60042.","journal-title":"PLoS One."},{"key":"300_CR8","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2165\/00003495-200565120-00011","volume":"65","author":"GW Robins","year":"2005","unstructured":"Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller\u2019s diarrhoea. Drugs. 2005;65:1697\u2013713.","journal-title":"Drugs"},{"key":"300_CR9","unstructured":"Salix Pharmacetuicals Inc. Xifaxan\u00ae (rifaximin): US prescribing information. 2011. http:\/\/www.salix.com\/assets\/pdf\/prescribe_info\/xifaxan-pi.pdf. Accessed 30 June 2014."},{"key":"300_CR10","unstructured":"Norgine Ltd. Targaxan 550\u00a0mg film-coated tablets: summary of product characteristics. 2013. http:\/\/www.medicines.org.uk\/emc\/medicine\/27427\/SPC\/TARGAXAN+550+mg+film-coated+tablets\/. Accessed 30 June 2014."},{"key":"300_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.phrs.2014.05.001","volume":"85","author":"C Blandizzi","year":"2014","unstructured":"Blandizzi C, Viscomi GC, Marzo A, et al. Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. Pharmacol Res. 2014;85:39\u201344.","journal-title":"Pharmacol Res."},{"issue":"8","key":"300_CR12","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1039\/b717887e","volume":"10","author":"GC Viscomi","year":"2008","unstructured":"Viscomi GC, Campana M, Barbanti M, et al. Crystal forms of rifaximin and their effect on pharmaceutical properties. CrystEngComm. 2008;10(8):1074\u201381.","journal-title":"CrystEngComm."},{"issue":"3","key":"300_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/1756283X11401774","volume":"4","author":"SL Flamm","year":"2011","unstructured":"Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Ther Adv Gastroenterol. 2011;4(3):199\u2013206.","journal-title":"Ther Adv Gastroenterol."},{"key":"300_CR14","first-page":"51","volume":"14","author":"JJ Descombe","year":"1994","unstructured":"Descombe JJ, Dubourg D, Picard M. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res. 1994;14:51\u20136.","journal-title":"Int J Clin Pharmacol Res."},{"key":"300_CR15","first-page":"1270A","volume":"54","author":"PL Golden","year":"2011","unstructured":"Golden PL, Pieniaszek HJ, Forbes WP. Steady-state rifaximin pharmacokinetics in patients with chronic liver disease and hepatic encephalopathy [abstract no. 1932]. Hepatology. 2011;54:1270A\u20131A.","journal-title":"Hepatology"},{"issue":"10","key":"300_CR16","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1592\/phco.27.10.1361","volume":"27","author":"HS Pentikis","year":"2007","unstructured":"Pentikis HS, Connolly M, Trapnell CB, et al. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy. 2007;27(10):1361\u20139.","journal-title":"Pharmacotherapy."},{"key":"300_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1345\/aph.1H395","volume":"41","author":"CB Trapnell","year":"2007","unstructured":"Trapnell CB, Connolly M, Pentikis H. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol\/norgestimate in healthy females. Ann Pharmacother. 2007;41:222\u20138.","journal-title":"Ann Pharmacother."},{"issue":"12","key":"300_CR18","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071\u201381.","journal-title":"N Engl J Med."},{"issue":"8","key":"300_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/j.1365-2036.2011.04808.x","volume":"34","author":"A Sanyal","year":"2011","unstructured":"Sanyal A, Younossi ZM, Bass NM, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34(8):853\u201361.","journal-title":"Aliment Pharmacol Ther."},{"key":"300_CR20","doi-asserted-by":"crossref","unstructured":"Berni E, Bannister C, Poole C, et al. The first evaluation of the relationship between the Chronic Liver Disease Questionnaire and the EQ-5D Index in hepatic encephalopathy patients treated with rifaximin-\u03b1 [poster no. PWE-154]. Meeting of the British Society of Gastroenterologists; 16\u201319 Jun 2014; Manchester.","DOI":"10.1136\/gutjnl-2014-307263.414"},{"issue":"5 Suppl","key":"300_CR21","first-page":"S451","volume":"144","author":"GW Neff","year":"2013","unstructured":"Neff GW, Barrett AC, Bortey E, et al. Efficacy and tolerability of rifaximin in hepatitis C patients with recurrent hepatic encephalopathy [abstract no. Su1300]. Gastroenterology. 2013;144(5 Suppl):S451\u20132.","journal-title":"Gastroenterology"},{"issue":"8","key":"300_CR22","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.cgh.2013.12.021","volume":"12","author":"KD Mullen","year":"2014","unstructured":"Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol. 2014;12(8):1390\u20137.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"300_CR23","unstructured":"Bannister CA, Conway P, Radwan A, et al. Patients experiencing repeated episodes of hepatic encephalopathy have increasing risk of death: a post hoc analysis of rifaximin-\u03b1 open label study [abstract]. British Association for the Study of the Liver Annual Meeting; 15\u201317 Sep 2014; Newcastle."},{"key":"300_CR24","unstructured":"Bannister CA, Conway P, Radwan A, et al. Patients experiencing repeated episodes of hepatic encephalopathy have increasing risk of subsequent episodes: a post hoc analysis of rifaximin-\u03b1 open label study [abstract]. United European Gastroenterology Week; 18\u201324 Oct 2014; Vienna."},{"issue":"5 Suppl","key":"300_CR25","first-page":"S451","volume":"144","author":"GW Neff","year":"2013","unstructured":"Neff GW, Flamm SL, Mullen KD, et al. Improved outcomes in hepatic encephalopathy using rifaximin monotherapy compared to rifaximin and lactulose combination therapy [abstract no. Su1298]. Gastroenterology. 2013;144(5 Suppl):S451.","journal-title":"Gastroenterology."},{"key":"300_CR26","unstructured":"Poole CD, Conway P, Nanuwa K, et al. Cost effectiveness of rifaximin-\u03b1 in the reduction of recurrence of overt hepatic encephalopathy [poster no. P451]. International Liver Congress, 49th Annual Meeting of the European Association for the Study of the Liver; 9\u201313 Apr 2014; London."},{"issue":"2","key":"300_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/MCG.0b013e318276be13","volume":"47","author":"GW Neff","year":"2013","unstructured":"Neff GW, Jones M, Jonas M, et al. Lack of Clostridium difficile infection in patients treated with rifaximin for hepatic encephalopathy: a retrospective analysis. J Clin Gastroenterol. 2013;47(2):188\u201392.","journal-title":"J Clin Gastroenterol."},{"key":"300_CR28","unstructured":"Medicines and Healthcare products Regulatory Agency. Public Assessment Report Decentralised Procedure. Refero 550\u00a0mg film-coated tablets: procedure no. UK\/H\/5075\/001\/DC. 2012. http:\/\/www.mhra.gov.uk\/SearchHelp\/GoogleSearch\/index.htm?q=rifaximin. Accessed 30 June 2014."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-014-0300-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0300-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:45:59Z","timestamp":1659113159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-014-0300-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,29]]},"references-count":28,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["300"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0300-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,29]]},"assertion":[{"value":"29 October 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}